Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Sorry, there are no financial reports available yet.
Investor presentations
Sorry, there are no events available.
Press Releases
ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update
press release
March 9, 2018
Pipeline Achievements in 2017 Included Progress with Three Phase 3 and Two Phase 2 Clinical Trials Key 2018 Clinical Milestones…
Read moreObsEva SA to Hold Fourth Quarter and Year-end 2017 Financial Results and Business Update Call on March 9, 2018
press release
March 2, 2018
Geneva, Switzerland and Boston, MA – March 2, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development…
Read moreObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting
press release
March 1, 2018
Oral administration of OBE022 shows favorable safety and results in predictable exposureNon-clinical results of OBE022 for PTL demonstrating fetal safety…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2021
May 28, 2021
ObsEva Annual General Meeting 2020
June 9, 2020
Upcoming Events
Stock Information
Latest Press Release
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 –…
Read moreInvestor Contact
Media Contact
Media
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Media
Sign up for news
